<DOC>
	<DOC>NCT02078219</DOC>
	<brief_summary>This study is to examine the hypothesis that administration of RDEA3170 to Japanese patients with gout or asymptomatic hyperuricemia in doses of 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg once daily, respectively will result in greater reduction of sUA compared to placebo.</brief_summary>
	<brief_title>Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Subject meets any of the following criteria and with sUA ≤10.0 mg/dL: 1. sUA level of &gt;7.0 mg/dL at 7 days prior to baseline with gout; 2. sUA level of ≥8.0 mg/dL at 7 days prior to baseline without gout but with complications (hypertension, ischemic heart disease, diabetes, metabolic syndrome); 3. sUA level of ≥9.0 mg/dL at 7 days prior to baseline without gout and complications. Subject with an acute gout flare that has not resolved at least 14 days prior to the baseline visit. Subject has a history or suspicion of kidney stones. Subject has an estimated creatinine clearance &lt;60 mL/min calculated by the Cockcroft Gault formula Subject is receiving strong or moderate CYP3A inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>